Insulin-Like Growth Factor-1 (IGF-1) Reduces Ischemic Changes and Increases Circulating Angiogenic Factors in Experimentally - Induced Myocardial Infarction in Rats.
Summary of "Insulin-Like Growth Factor-1 (IGF-1) Reduces Ischemic Changes and Increases Circulating Angiogenic Factors in Experimentally - Induced Myocardial Infarction in Rats."
ABSTRACT:
BACKGROUND:
Coronary artery disease is a global health concern in the present day with limited therapies. Extensive efforts have been devoted to find molecular therapies to enhance perfusion and function of the ischemic myocardium. Aim of the present study was to look into the effects of insulin like growth factor -1 (IGF-1) on circulating angiogenic factors after myocardial ischemia in rats.
METHODS:
Adult male Sprague-Dawley rats were randomly divided into 10-days control, myocardial infarction, IGF-1 alone (2 ug/rat/day) and ISO+IGF-1 groups. Isoproterenol (ISO), a synthetic catecholamine was used to induce myocardial infarction. Serum transforming growth factor-beta (TGF-beta) and vascular endothelial growth factor (VEGF) levels were checked after 10-days of IGF-1 administration.
RESULTS:
There was a significant increase in heart weight after IGF-1 treatment. A significant increase in cardiac enzyme level (CK-MB and LDH) was seen in isoproterenol treated rats when compared to control group. IGF-1treatment induced a significant increase in serum angiogenic factors, IGF-1, VEGF and TGF beta levels. IGF-1 also reduced the ischemic changes in the myocardium when compared to the isoproterenol alone treated group.
CONCLUSIONS:
In conclusion, treatment with insulin-like growth factor-1 (IGF-1) in myocardial infarction significantly increased circulating angiogenic growth factors like IGF-1, VEGF and TGF beta thus, protecting against myocardial ischemia.
Affiliation
Journal Details
This article was published in the following journal.
Name: Vascular cell
ISSN: 2045-824X
Pages: 13
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21651821
- DOI: http://dx.doi.org/10.1186/2045-824X-3-13
Medical and Biotech [MESH] Definitions
Insulin-like Growth Factor Ii
A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults.
Insulin-like Growth Factor I
A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor.
Insulin-like Growth Factor Binding Protein 3
One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.
Insulin-like Growth Factor Binding Protein 5
One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.
Insulin-like Growth Factor Binding Protein 2
One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.
PubMed Articles
ABSTRACT: INTRODUCTION: Adult Growth hormone Deficiency is a well known phenomenon effecting both males and females. Adult Growth Hormone Deficiency is marked by a number of neuropsychiatric, cognitiv...
Insulin/insulin-like growth factor (IGF-1) signaling is important for a variety of age-related processes. However, whether or not it affects atherosclerosis is unknown.
Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis.
Obesity-associated carcinogenesis is postulated to be mediated through the proliferative actions of insulin and the insulin-like growth factor (IGF) family. The aim of this study was to determine whet...
The Relationship between Insulin Resistance and Hypercoagulability in Acute Ischemic Stroke.
Aim: Insulin resistance has effects on the coagulation system, which is important in the acute phase of infarct. We examined the relationships between insulin resistance, hemostatic markers and stroke...
Clinical Trials
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance
OBJECTIVES: I. Determine the efficacy and toxic effects of recombinant human insulin-like growth factor I (rhIGF-I) on carbohydrate tolerance, insulin action, insulin secretion, hyperandro...
OBJECTIVES: I. Determine if mutations in the gene encoding the insulin-like growth factor-I receptor lead to relative insulin-like growth factor-I insensitivity and produce intrauterine g...
Insulin-like Growth Factor-1 (IGF-1) in Amyotrophic Lateral Sclerosis (ALS) Trial
The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study particip...
The trial will investigate the treatment of growth failure in children with Noonan syndrome. Abnormalities in the growth hormone (GH) – insulin-like growth factor-I (IGF-I) axis resultin...
This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of p...
